Skip to main content

Cullinan Therapeutics, Inc.

corporate_fare Company Profile

Cullinan Therapeutics, Inc.

CGEM·NASDAQ·Life Sciences·CIK 0001789972

We are a biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. We specialize in T cell engagers, which are used in oncology and are now being applied to autoimmune diseases. Our clinical-stage pipeline is built on a scientific approach and innovation, aiming to deliver new standards of care for patients. In Immunology, we are developing CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases. The Phase 1 OUTRACE Program is evaluating CLN-978 in patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren's disease (SjD). The OUTRACE SLE Study is a global Phase 1 clinical trial for moderate to severe SLE. The OUTRACE RA Study is a Phase 1 clinical trial for active, difficult-to-treat RA, ongoing in Europe. The OUTRACE SjD Study is a global Phase 1 clinical trial for active, moderate to severe Sjögren's disease. We are also developing Velinotamig, a BCMAxCD3 bispecific T cell engager for autoimmune diseases. Chongqing Genrix Biopharmaceutical Co., Ltd. (Genrix), our licensor, is conducting a Phase 1 clinical trial in China for autoimmune diseases, starting with SLE and planning future expansion. We plan to use this data to accelerate global clinical development and will conduct all further development of velinotamig in autoimmune diseases after Genrix completes its Phase 1 trial. In Oncology, our program includes CLN-049, a FLT3xCD3 bispecific T cell engager.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CGEM at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • FDA Accepts Zipalertinib NDA, Sets Feb 2027 PDUFA Date; Cullinan Therapeutics Details Q1 & Pipeline
  • Cullinan Therapeutics Establishes New $200M At-The-Market Equity Offering Program
  • Cullinan Therapeutics Files 10-K, Details Zipalertinib NDA Submission, Fast Track, and Cash Runway into 2029
  • Cullinan Therapeutics Reports FY25 Results, Strong Cash Runway, and Key Pipeline Milestones
  • Cullinan Therapeutics Reports Strong Cash Position and Key Pipeline Milestones, Including Fast Track and NDA Progress

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$219.88M
Op. Cash Flow
-$175.75M
Free Cash Flow
-$175.8M
Operating Income
-$241.65M
Cash & Equivalents
$88.33M
Debt / Equity
0.00×
Shares Outstanding
60.24M sh
Source: 10-K · filed 2026-03-10 · accession 0001193125-26-099362
$8.96 +0.79% today
52-week range · as of 2026-10-01 $5.68 – $23.19
Market cap
$577.15M
Volume
1M (1.1× avg)
3-mo avg 887.9K
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CGEM - Filings & News (Page 2)

CGEM
May 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $15.15
Real-time Price: $8.96 info
Change: -$6.19 (-41%) info
Market Cap: $577.147M info
CGEM
Apr 28, 2026, 7:52 AM EDT
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $13.30
Real-time Price: $8.96 info
Change: -$4.34 (-33%) info
Market Cap: $577.147M info
CGEM
Mar 10, 2026, 7:26 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $15.44
Real-time Price: $8.96 info
Change: -$6.48 (-42%) info
Market Cap: $577.147M info
CGEM
Mar 10, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.44
Real-time Price: $8.96 info
Change: -$6.48 (-42%) info
Market Cap: $577.147M info
CGEM
Jan 08, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.05
Real-time Price: $8.96 info
Change: -$2.09 (-19%) info
Market Cap: $577.147M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets